Journal of Transplantation

Clinical Study

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

Table 2

Time course of immunosuppressive agents in cardiac transplant recipients receiving low-dose EVL (LD) or high-dose EVL (RD).
Parameter 𝑇 0 𝑇 1 𝑇 3 𝑇 6 𝑇 9 𝑇 1 2 𝑃 value
Everolimus (μg/L)
LD group— 4 . 3 4 ± 2 . 6 3 3 . 5 9 ± 1 . 4 4 *** 3 . 6 6 ± 2 . 0 6 *** 3 . 3 4 ± 1 . 2 2 *** 3 . 1 0 ± 1 . 0 2 *** 0.139
RD group— 5 . 2 2 ± 2 . 6 3 5 . 7 6 ± 2 . 5 3 6 . 2 4 ± 2 . 4 9 5 . 3 1 ± 1 . 8 6 5 . 2 8 ± 2 . 0 1 0.096
CSA (μg/L)
LD group 1 0 2 . 0 ± 3 1 . 5 7 0 . 1 ± 3 8 . 8 5 1 . 0 ± 1 5 . 6 5 1 . 4 ± 1 9 . 5 4 7 . 8 ± 1 8 . 8 4 3 . 1 ± 1 3 . 6 <0.001
RD group 9 1 . 3 ± 2 6 . 1 6 0 . 3 ± 3 0 . 0 4 8 . 2 ± 2 7 . 8 5 0 . 6 ± 2 7 . 5 4 8 . 8 ± 2 2 . 4 4 3 . 1 ± 1 9 . 7 <0.001
TAC (μg/L)
LD group 9 . 1 0 ± 2 . 1 0 6 . 4 9 ± 2 . 9 1 5 . 2 6 ± 1 . 4 2 5 . 7 4 ± 2 . 3 6 4 . 4 8 ± 0 . 9 4 4 . 7 5 ± 1 . 1 0 <0.001
RD group 8 . 8 8 ± 2 . 1 4 6 . 7 1 ± 2 . 6 9 4 . 8 9 ± 1 . 4 2 4 . 6 8 ± 1 . 2 8 5 . 2 0 ± 2 . 1 8 5 . 6 7 ± 1 . 8 8 <0.001
***Significant different from RD group at the same time point.